Rep. Gilbert Ray Cisneros Jr. (D-CA) Sells AtriCure (ATRC) Stock

Rep. Gilbert Ray Cisneros Jr., a Democrat from California's 31st district, sold shares of AtriCure, Inc. (NasdaqGM: ATRC) on September 29, 2026. The transaction was valued between $1,001 and $15,000 and was reported on October 12, 2026.

Recent Trading Activity

Cisneros's recent sale fits a pattern of trading activity. Earlier in 2026, he sold shares of Workday and W. R. Berkley Corporation, indicating a trend in his portfolio management.

Other Institutional Activity in AtriCure

BlackRock Inc. holds 4,474,548 shares of AtriCure, worth about $250.9 million after adding 431,769 shares, a 10.7% increase. Wellington Management Group, LLP owns 3,495,603 shares valued at approximately $196 million, having increased its stake by 112,980 shares, a 3.3% rise. Vanguard Portfolio Management LLC also boosted its holdings by 424,581 shares, bringing its total to 3,127,195 shares worth about $175.3 million, a 15.7% increase. However, Hood River Capital Management LLC reduced its stake by 212,309 shares, ending with 2,905,299 shares valued at around $162.9 million, a decrease of 6.8%. AllianceBernstein L.P. cut its position by 490,452 shares, leaving it with 2,768,365 shares worth about $155.2 million, a 15.0% decrease.

AtriCure, Inc. Stock Down 0.6%

AtriCure's stock recently traded around $57.45 as of October 16, 2026. This price is above its 50-day moving average by about 10.1% and significantly above its 200-day average by 55.2%. However, it's about 6.9% below its 52-week high of $61.70, indicating some volatility in the stock.

Recent Earnings

AtriCure reported trailing twelve-month revenue of approximately $569.6 million, with a net margin of 1.9%. The company has an earnings per share (EPS) of $0.21. Its next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at AtriCure, Inc.

Several insiders have sold shares recently. Salvatore Privitera, the Chief Technology Officer, sold 7,763 shares at an average price of $52.50 on September 2, 2026, valued at about $407,558. He sold another 3,657 shares at $55.00 on September 8, 2026, for approximately $201,135. Regina E. Groves, a Director, sold 5,313 shares at $54.22 on September 11, 2026, totaling about $288,071. Privitera also sold 4,519 shares at $60.00 on September 23, 2026, valued at approximately $271,140.

Analysts Set New Price Targets

On July 28, 2026, UBS maintained its "Buy" rating with a price target of $50.00, down from $55.00. BTIG also maintained a "Buy" rating with a target of $55.00 on August 24, 2026, raised from $45.00. Piper Sandler rated the stock "Overweight" with a target of $60.00 on August 27, 2026, up from $50.00. Needham maintained a "Buy" rating with a target of $64.00 on September 2, 2026, increased from $45.00. However, Freedom Capital Markets downgraded the stock to "Hold" with a target of $57.00 on October 2, 2026.

About AtriCure

AtriCure, Inc. develops and sells medical devices for surgical procedures, especially focused on cardiac tissue and pain relief. The company is headquartered in Mason, Ohio, and has about 1,350 employees. Its innovations are crucial for medical centers both in the U.S. and internationally, especially in the healthcare sector.

Bottom Line

As AtriCure prepares for its next earnings report on November 3, 2026, investors will be watching for further trading activity from insiders and any updates from analysts regarding the stock's performance.